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NanoparticlesAbstract Nanoparticles are being increasingly used in the ﬁeld of cancer treatment due to their
unique properties and advantages. The aim of the present research work was to prepare and char-
acterize a polymeric albumin nanosystem for Cisplatin and evaluate its in-vitro efﬁcacy against
B16F10 melanoma. The developed nanoparticles were almost spherical in shape with a particle size
in the range of 150–300 nm, low polydispersity values and about 80% drug entrapment efﬁciency.
Albumin nanocarriers sustained the release of Cisplatin for more than 48 h, suggesting the reduc-
tion in dosing schedule for this drug. The results from in-vitro cell line studies indicated the dose
dependent cytotoxic potential of drug loaded albumin nanoparticles, their potential to inhibit cell
proliferation and induce morphological changes. In addition, these nanoparticles exhibited superi-
ority to Cisplatin in hampering the cell migration. Developed nanoparticles caused cell cycle arrest
along with time and concentration dependent cellular uptake in B16F10 cell line. These results sig-
nify that the prepared Cisplatin albumin nanoparticles could serve as a promising approach for
B16F10 melanoma treatment.
ª 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Metastasis is a terminology related to the diffusion of cancer-
ous cells from their primary location to distant sites within the
body (Fidler and Hart, 1982). Metastatic melanoma, owing to
its aggressive nature, is regarded as one of the most severe
types of skin cancer with high morality rates. These cells inter-
act with healthy host cells in a stepwise fashion, with adhesion
and invasion to the basement membrane along with extracellu-
lar matrix degradation (Lee et al., 2006; Cavallaro and
342 S.S. Shrikhande et al.Christofori, 2001). In United States alone, melanoma led to
death of approximately 9000 patients in the year 2012, with
threefold increase in number of cases since the year 1970
(Cancer Facts and Figures, 2012).
Numerous treatment options have been employed for mel-
anoma such as surgery, radiation, chemotherapy and biologic
therapeutics (Drugs for Melanoma, 2013). However, due to the
high metastatic potential of these cancer cells and their resis-
tance to conventional anticancer agents, in addition to poor
diagnosis, the effective therapy of melanoma remains disap-
pointing. Owing to the rise in number of melanoma cases,
development of alternative methodologies with enhanced
safety and efﬁcacy, for rehabilitation of melanoma is the need
of time.
Cisplatin, an alkylating agent has been successfully used
since decades for the treatment of variety of cancers viz. bone
cancer, lung cancer, head and neck cancer, sarcomas and ovar-
ian tumors (Floria and Busselberg, 2011). This moiety interca-
lates with the DNA and causes conformational changes in its
structure, thus leading to cell death. Cisplatin per se exhibits
moderate activity against metastatic melanoma and is used
as a single line treatment or in combination therapy with other
antitumor agents. Alone, this drug has exhibited a response
rate of about 10% in patients; however, combination of the
same with dacarbazine, tamoxifen and amifostine has led to
an increase in overall survival rate of melanoma patients
(Del Prete et al., 1984; Glover et al., 1987). Conversely, Cis-
platin because of its short term action on melanoma cells with
associated nephrotoxicity and ototoxicity has proved to be
futile for the patients in a long term perspective. One of the
approaches to alter the pharmacokinetic proﬁle and toxicity
related to this drug is to formulate it in the form of novel deliv-
ery systems such as polymeric nanoparticles, micelles, lipo-
somes, nanoemulsions, dendrimers and lipid nanocarriers.
Polymeric nanocarrier systems are of advantage in drug
delivery arena due to their inherent biodegradability, ability
to reduce drug toxicity, prevention of drug degradation and
controlled release characteristics (Kreuter, 1994). Human
serum albumin is one such biocompatible polymer approved
by the food and drug administration for use in injectable prep-
arations. Albumin is extensively used for nanoparticle synthe-
sis due to its low cost, biocompatibility, ease of availability and
ease of puriﬁcation.
Due to the multiple advantages of albumin, incorporation
of Cisplatin in these nanoparticles is expected to reduce its
unwanted side effects with concomitant enhancement in efﬁ-
cacy. With this objective in mind, the present work was direc-
ted toward preparation of Cisplatin nanoparticles and
evaluation of their anticancer potential in comparison with
the plain drug in B16F10 melanoma cells.
2. Experimental
2.1. Materials
Cisplatin was obtained as a gift sample from Cipla Pvt Ltd,
Mumbai, India. Sterile human serum albumin, 20% solution
(Buminate, Baxter) was purchased from Lifeline Pharma,
Mumbai, India. Absolute ethanol and Glutaraldehyde were
obtained from Merck Pvt Ltd, India. B16F10 murine mela-
noma cell line was obtained from National center for cell sci-ences, Pune, India. The above cell line was maintained in
10% DMEM (Cell Clone, Genetix Biotech Asia Pvt Ltd,
India) with Fetal Bovine serum (GIBCO BRL, MD, USA),
penicillin (100 U/ml) and Streptomycin (100 g/ml). Cells were
grown in humidiﬁed condition of 5% CO2 at a temperature
of 37 C. All other reagents and chemicals were of analytical
grade.2.2. Preparation of human serum albumin Cisplatin
nanoparticles
Human serum albumin nanoparticles were prepared by a
desolvation process as per the procedure described earlier in
the literature with some modiﬁcations (Langer et al., 2008).
Brieﬂy, drug was added to 2% w/v aqueous human serum
albumin solution and mixed on a magnetic stirrer for 30 min.
Absolute ethanol was added to the above solution to desolvate
the protein in the ratio of 1:2. Formation of coacervates was
indicated by slight turbidity in the solution. The formed nano-
particles were hardened with 8% glutaraldehyde and stirred
for 4 h for covalent crosslinking. Formed nanoparticles were
subjected to a puriﬁcation process by ultracentrifugation
(Optima L-100 XP, Beckman Coulter, Inc) at 30,000 rpm.
Blank batches for the nanoparticles were prepared in a similar
manner except for the drug addition step. Puriﬁed nanoparti-
cles were subjected to lyophilization with 5% sucrose and
stored under refrigeration until further use.2.3. Determination of particle size, polydispersity index and zeta
potential
Average particle size of developed albumin nanoparticles was
analyzed by photon correlation spectroscopy using Malvern
Zetasizer instrument, 90S (Ver 6.12.). The sample (Quantity-
20 ll) was diluted with double distilled water in the polystyrene
cuvette and was placed in the path of scattered light. The scat-
tered intensity measured at an angle of 90 was determined by
the software to give the hydrodynamic diameter. Zeta poten-
tial was measured using a dip cell at a temperature of 25 C.
2.4. Determination of entrapment efﬁciency of Cisplatin in
nanoparticles
Entrapment efﬁciency of the developed nanoparticles was
determined after ultracentrifugation at 30,000 rpm (4 C,
1 h). Amount of Cisplatin entrapped in the nanoparticles
was calculated by subtracting the amount of free drug in the
supernatant from the initial concentration of Cisplatin used
in the preparation of formulation. Amount of free Cisplatin
present in the supernatant was estimated using UV spectro-
photometer by a colorimetric method after reaction with o-
phenylenediamine at 703 nm with minor modiﬁcations (Golla
and Ayres, 1973).
2.5. Determination of morphology of the developed nanoparticles
2.5.1. Scanning electron microscopy (SEM)
A drop of nanoformulation was placed on a specimen holder
and kept for drying. The dried sample was then coated with
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specimen chamber for viewing of particles.
2.5.2. Transmission electron microscopy (TEM)
Morphology of the nanoparticles was investigated using
Transmission electron microscopy (CM200 machine, PHILIPS
Model) operated at voltage of 20–200 kV with a resolution of
2.4 A˚. A drop of nanoparticle solution was placed on the cop-
per slide of the instrument provided with carbon grids. The
sample was allowed to dry on the slide, introduced into the
instrument and scanned under the microscope for viewing of
particles.
2.6. In-vitro drug release studies
Cisplatin albumin nanoparticle dispersion (2 ml) was placed
inside a dialysis bag with molecular weight cutoff of 12–
14 kDa (Himedia Laboratories Pvt Ltd, Mumbai). Dialysis
bag was tied and placed in a beaker containing 100 ml of phos-
phate buffer saline 7.4, maintained at 37 C and stirring under
100 rpm. Dissolution medium (2 ml) was withdrawn at suitable
time intervals and replaced with same volume of fresh dissolu-
tion medium. Amount of Cisplatin in the release medium was
determined by a colorimetric method as described above. All
the dissolution measurements were done in triplicate.
2.7. In-vitro studies on B16F10 cell line
2.7.1. Determination of cell viability by MTT assay
Cell viability for B16F10 cells was measured as per the proce-
dure described earlier (Dua and Gude, 2006). B16F10 cells
were seeded in 96 well plates at a concentration of 4 · 103 -
cells/100 ll/well and incubated for 24 h. These cells were then
treated with Cisplatin, Blank nanoparticles and Cisplatin poly-
meric nanoparticles for 24, 48, 72 and 96 h at concentrations
ranging from 0.1 lg/ml to 100 lg/ml for determination of
IC50. After treatment, the cells were washed with phosphate
buffer saline and MTT (Sigma Aldrich, USA) was added in
the plates at a concentration of 5 mg/ml. The formed formazan
crystals were solubilized in DMSO and the optical density was
measured using ELISA microplate reader (Molecular devices,
Spectra Max 190) at 540 nm after background correction at
690 nm.
2.7.2. Colony formation assay
For colony formation assay, 35 mm petri plates were seeded
with 600 cells/plate and allowed to proliferate for 48 h. Later,
these cells were treated for 24 h with the sub-toxic concentra-
tions of pure drug, blank and drug loaded formulation. Com-
plete DMEM medium was added after PBS washing of the
treated cells. Petri plates were incubated for approximately
3–4 days, and cells were ﬁxed using methanol and stained with
0.2% crystal violet solution for visual observation of colonies.
Colonies with 50 or more number of cells were counted and
percent inhibition potential for the colonies by the developed
formulations was calculated.
2.7.3. Wound healing assay
Wound healing assay was carried out as per an earlier proce-
dure with minor modiﬁcations (Dua and Gude, 2008).B16F10 cells were seeded at a concentration of 4 · 104 cells/
ml in 35 mm petri plates and allowed to grow up to 60–70%
conﬂuency. Sub-toxic concentrations of above mentioned for-
mulations were added in the above plates and incubated for
24 h. Later, wounds were created in the above plates using a
microtip. The cells were washed with PBS for 2–3 times to
remove the peeled cells from the surface and initial wound
width was measured using an ocular grid. After incubation
period of 24 h, the cells were ﬁxed with methanol, observed
for migration and the images were taken using an inverted
microscope (Axiovision, Zeiss). Twenty-ﬁve measurements
were recorded for each formulation and percent migration
for each of the formulations was calculated considering migra-
tion in untreated control as 100%.
2.7.4. Determination of cellular morphology by leighton tube
assay
Leighton tube assay was carried out as per the procedure
described earlier (Shenoy et al., 2013). B16F10 melanoma cells
were grown in 35 mm petri plates on coverslips in DMEM
medium. Sub-toxic concentrations of pure drug, blank albu-
min nanocarriers and drug loaded formulations were added
in the above plates and incubated for 48 h. Later, these cells
were ﬁxed with 70% ethanol and stained with hematoxylin
and eosin. The coverslips were dipped lightly in xylene to
remove the excess stain and ﬁxed on glass slides using DPX
mounting medium. The changes in B16F10 morphology cells
after treatment were observed under the inverted light
microscope.
2.7.5. Cell cycle analysis by ﬂow cytometry
For cell cycle analysis, sub-toxic amounts of pure Cisplatin
and developed nanoformulations were added to 35 mm plates
containing sub-conﬂuent B16F10 cells after 48 h incubation
period. These cells were collected, cleaned 2–3 times with
PBS and ﬁxed with chilled 70% ethanol. The obtained cell pel-
let was subjected to treatment with RNAse (MBI Fermentas,
USA) and stained with propidium iodide. Cell cycle analysis
was performed on Becton–Dickinson FACS scan and data
were analyzed using MODFIT software.
2.7.6. Determination of qualitative cellular uptake of
nanoparticles by confocal microscopy
For this particular study, the nanoparticles were loaded with
FITC dye in the concentration of 0.2 mg/ml. B16F10 cells were
allowed to reach 60% conﬂuency and were treated with the
plain dye and dye loaded albumin nanoparticles respectively
for 2 h. These cells were ﬁxed with 1% paraformaldehyde sub-
sequent to PBS washings. Further, the cells were treated with
DAPI and washed thrice with PBS. The coverslips containing
B16F10 cells were observed under the microscope after treat-
ment with 2.5% DABCO and were sealed by utilizing nail
paint. Acquisition was performed using confocal microscope
at 63X. (LSM 510, Zeiss). Analysis of the data was done using
LSM image browser software.
2.7.7. Determination of quantitative cellular uptake of
nanoparticles in B16F10 cells by ﬂow cytometry
Quantitative assessment was performed for uptake of nano-
particles loaded with coumarin-6 dye (0.6 mg/ml). B16F10
Figure 2 Scanning electron microscopy of developed
nanoparticles.
Figure 1 Transmission electron microscopy imaging of albumin
nanoparticles.
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conﬂuency. Conﬂuent cells were treated with plain dye and
dye loaded nanocarriers for speciﬁc time limit as in a particular
study (Jain et al., 2013). After harvesting, these cells were ﬁxed
using 1% PFA solution. Cells were suspended in PBS solution
subsequent to washings with the same solvent. Analysis was
performed on FACS Calibur using CellQuest software.
2.8. Statistical analysis
All the measurements for the present work were performed in
triplicate. Statistical analysis was performed using the software
Graphpad Instat, Version 3.10. Results of the same are
expressed as mean ± S.D. One-way ANOVA was used to
determine the signiﬁcant difference between the treatment
groups and untreated control (p< 0.001).
3. Results and discussion
3.1. Particle size, polydispersity index and zeta potential
measurements for developed nanoparticles
Human serum albumin nanoparticles were synthesized using a
desolvation method. Developed albumin nanoparticles were
found to exhibit particle size in the range of 150–300 nm with
low polydispersity values indicating homogeneity in the
formed nanocarriers. The results for particle size analysis are
as given in Table 1. Thus, the prepared nanoparticles were
ideal candidates for enhanced permeability and retention
mechanism for tumor delivery. There was a slight increase in
the particle size and polydispersity index in the drug loaded
formulations as compared to blank nanoparticles due to the
presence of the drug. However, there was not much change
in the zeta potential values of both the formulations due to
the unionized nature of the drug moiety. Zeta potential values
were in the negative range due to the acidic albumin, which
exhibited negative potential values at pH 7.4.
Human serum albumin nanoparticles exhibit poor stability
per se in solution form. Also, it is well known that during the
freezing process of a particular sample, there is a phase separa-
tion into ice and cryo-concentrated solution. Furthermore, the
crystallization of ice may exert a mechanical stress, leading to
destabilization of nanoparticles (Abdelwahed et al., 2006). For
these reasons, sucrose was added to the suspension of nano-
particles before freezing. There was only a minor increase in
the particle size of the nanoformulations after lyophilization,
indicating suitability and rigidity of the freeze drying process.
3.2. Determination of entrapment efﬁciency of Cisplatin in
nanoparticles by colorimetry
Entrapment efﬁciency of Cisplatin in nanoparticles was found
to be in the range of 70–80%. Although Cisplatin is a hydro-Table 1 Determination of particle size, polydispersity index and ze
Formulation Particle size (nm)
Blank nanoparticles 193.34 ± 2.416
Cisplatin HSA nanoparticles 265 ± 1.1476phobic moiety, it showed good entrapment in albumin nano-
particles. This phenomenon may be attributed to the high
plasma protein binding efﬁciency of Cisplatin in the blood
(Ivanov et al., 1998).
3.3. Transmission and scanning electron microscopy imaging
TEM images of developed nanoparticles showed the presence
of irregular and discrete particles whereas SEM image showed
presence of irregular to almost spherical particles. Particle size
of the nanoparticles obtained with TEM and SEM was in well
correlation to the particle size data obtained by zetasizer. The
results for TEM and SEM are as depicted in Figs. 1 and 2
respectively.ta potential for the developed albumin nanocarriers.
Polydispersity index Zeta potential (mV)
0.1266 ± 0.05 16.96 ± 1.05
0.115 ± 0.013 15.6 ± 1.285
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Pure Cisplatin exhibited complete release within 2 h due to its
short half life. Drug release for the nanoparticulate formula-
tion depicted a biphasic pattern wherein the nanoparticles
exhibited a sustained release pattern for more than 48 h. It
was observed that around 30% of the drug released within ﬁrst
2 h followed by sustained release of Cisplatin from polymer
matrix. These results suggest that the cytotoxicity of Cisplatin
would be reduced due to slow release of the drug from the
nanoparticles with concomitant reduction in frequency of dos-
ing and increase in patient compliance. The results for the dis-
solution studies are as depicted in Fig. 3.
3.5. In-vitro studies on B16F10 cell line
3.5.1. Developed nanoparticles exert cytotoxicity & inhibit the
proliferation of B16F10 cells
MTT assay was performed to determine the B16F10 cell viabil-
ity after treatment with the plain drug as well as drug loaded
nanoparticles based on time and concentration. The IC50 val-(c)   
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Figure 4 Effects of Cisplatin and Cisplatin albumin nanoparticles on
viability and (d) 96 h viability.ues for Cisplatin after 24, 48, 72 and 96 h were found to be
5 lg/ml, 2 lg/ml, 0.5 lg/ml and 0.4 lg/ml respectively. Hence
it was seen that Cisplatin was able to hamper the cell growth
in a time and concentration dependent manner wherein almost
100% of the cells were killed after 96 h. IC50 values for Cis-
platin loaded nanocarriers after 24, 48, 72 and 96 h were found
to be 45 lg/ml, 15 lg/ml, 5 lg/ml and 4 lg/ml respectively.
Developed nanoparticles were able to inhibit the cell prolifer-
ation slowly over 96 h time period due to the slow release of
Cisplatin from the albumin nanoparticles as exempliﬁed from
the dissolution proﬁle. Also, the blank nanoparticle formula-
tion presented an IC50 value greater than 1000 lg/ml in
B16F10 cells, proving the safety of formulation excipients
and absence of any background toxicity. The results for
MTT assay are as presented in Fig. 4. Based on the results
of MTT assay, the sub-toxic IC20 and IC50 concentrations of
Cisplatin and Cisplatin albumin nanoparticles were selected
for further studies and are as shown in Table 2.
3.5.2. Nanoparticles hamper the formation of colonies in B16F10
melanoma
Cancerous cells are prone to formation of colonies form a sin-
gle cell due to their inherent property of uncontrolled division
and proliferation (Franken et al., 2006). In the present work,
clonogenic assay was performed at IC20 and IC50 concentra-
tions for the drug as well as formulations. A concentration
dependent decrease in the formation of colonies was observed
for both i.e. Cisplatin and Cisplatin loaded nanoparticles.
Interestingly, the numbers of colonies were found to be less
than 50 in number for the above groups. Hence, the nanopar-
ticle formulation was comparable in terms of efﬁcacy with Cis-
platin in inhibiting the colony formation. The number of
colonies in the blank formulation was found to be
261 ± 15.71, similar to the untreated control i.e.
254.66 ± 4.16. The results for clonogenic assay are as given
in Fig. 5.(b)
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Table 2 Inhibitory concentrations (24 h) for developed for-
mulation and Cisplatin as calculated from MTT assay.
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Figure 5 (A) Pictographic representation of the clonogenic assay
nanoparticles, C: blank albumin nanoparticles, 1: IC20 concentratio
reduction in the number of colonies for the treatment groups in comp
346 S.S. Shrikhande et al.3.5.3. Nanoparticles inhibit cellular migration in wound scratch
assay
Cellular migration is an important phenomenon in cancer pro-
gression since the metastasis of tumor occurs in this manner. In
the present study, wound healing assay was performed at IC20
and IC50 concentrations to examine the potential of Cisplatin
and the developed nanocarriers to inhibit the above process.A2
B2 C
(A)
(B)
         Nanoparticles 
(14 µg/ml)
Nanoparticle 
(45 µg/ml)
Blank 
nanoparticles
 assay
ulaons
**
UC: untreated control, A: pure Cisplatin, B: Cisplatin albumin
n, 2: IC50 concentration and (B) comparative evaluation of the
arison with control (*P< 0.001).
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cellular migration at IC20 and IC50 concentrations (79.45%
at 1.3 lg/ml and 75.41% at 5 lg/ml respectively). However,
the developed nanoparticles effectively reduced the cellular
motility at both the sub-toxic levels as compared to Cisplatin(a)
(c)
(e)
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Figure 6 (A) Pictographic representation of effect of pure drug and
(b) pure drug IC20, (c) pure drug IC50, (d) nanoparticles IC20, (e)
evaluation of the percent wound coverage for the treatment groups inalone i.e. the inhibition in cellular migration was 45% at
14 lg/ml and 22.865% at 45 lg/ml for the developed Cisplatin
nanoformulation thus emphasizing its superiority over pristine
drug for therapy of cancer. Additionally, the blank nanoparti-
cles did not exhibit any reduction in B16F10 cell migration,(b)
(d)
(f)
)
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developed nanoparticles on cellular motility (a) untreated control,
nanoparticles IC50, (f) blank nanoparticles and (B) comparative
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Figure 7 Changes in the B16F10 cellular morphology by treatment groups (a) untreated control, (b) blank formulation, (c) Cisplatin
treated cells and (d) Cisplatin nanoparticulate formulation.
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trol (94.66% migration in comparison with control group).
The results for wound scratch assay are presented in Fig. 6.
3.5.4. Nanoparticles instigate changes in the morphology of
B16F10 cells
Leighton tube assay was carried out for the pure drug as well
as the drug loaded nanoparticles to assess the potential of
nanosystems to cause changes in the cellular morphology in
comparison with the pure drug. From Fig. 7, it can be seen
that both the drug and drug loaded nanoformulations caused
changes in the cell structure, swelling of cells, spindle forma-
tion and consequent cell damage with equivalent efﬁcacy.
Additionally there is a decrease in the population of B16F10
cells in the treatment groups compared to untreated control.
However, blank nanoparticles act parallel to the control group
and do not depict any morphological changes.
3.5.5. Developed nanoparticles cause cell cycle arrest in B16F10
melanoma
Alkylating agents like Cisplatin are known to cause pro-
grammed cell death by inhibiting the cells in G2 phase of cell
cycle (Cepeda et al., 2007). These results were reinstated by
the present study wherein dose dependent increase in Cisplatin
induced G2/M phase arrest was seen in B16F10 melanoma
(Fig. 8). The developed nanoparticles also exhibited dose
dependent increase in the G2/M phase leading to cell death.
The percentage of cells in the G2/M phase was found to be less
for nanoparticles than the pure drug group probably because
of the sustained release of drug from nanoparticles, leading
to slower rate of action. Additionally, the concentration of
nanoparticles was seen to increase in the S phase in nanopar-
ticle formulation IC50 group, suggesting their ability to hinderthe production of DNA in S phase of cell cycle in addition to
the cell division process. Hence, the developed nanoparticles
were found to be superior to pure drug by acting on different
phases of cell cycle.3.5.6. Nanoparticles are uptaken effectively by B16F10 cells in
confocal microscopy
In this study, the nucleus of the cells was stained using DAPI
and FITC just surrounded the cells in the overlay images.
FITC per se is not able to transverse the cells due to its hydro-
philic nature (Fig. 9). However, when the nanoparticles were
loaded with this particular dye, ﬂuorescence was observed in
the B16F10 cells indicating that nanoparticles are able to
enhance the penetration of FITC in the cancer cells. These
results indicate that the nanoparticles are able to modulate
the properties of antineoplastic drugs and enhance their uptake
in cancer cells.3.5.7. Nanoparticles show time and concentration dependent
uptake in B16F10 cells in ﬂow cytometry studies
Flow cytometry analysis was performed to evaluate the
uptake of developed nanoparticles in B16F10 cells
(Fig. 10). It was observed that albumin nanoformulations
were uptaken in the B16F10 cells in a time and concentra-
tion dependent manner. MFI of the albumin nanoparticles
at a concentration of 2.5 lg/ml for 15 min was found to
be 28.67 units, which was enhanced to 47.89 units after
30 min. Similarly, the MFI was 53.79 units and 91.26 units
for similar time points at a concentration of 5 lg/ml. Hence,
the developed nanoformulations were readily taken up by
the melanoma cells and would prove effective when used
in the remedy of melanoma.
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Figure 8 (A) Cell cycle analysis by Flow cytometry (a) untreated control, (b) Cisplatin IC20, (c) Cisplatin IC50, (d) nanoparticles IC20,
(e) nanoparticles IC50 and (B) comparative evaluation of the percentage of cells after treatment in different cell cycle phases for the
treatment groups in comparison with control (*P< 0.001).
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Cisplatin, although a well known moiety for melanoma treat-
ment, is associated with side effects during treatment and
exhibits less activity against the same. Formulation of Cis-
platin in the form of nanoparticles is expected to cause an
improvement in its activity. Hence, the present work was
undertaken to compare the efﬁcacy of Cisplatin with its poly-meric nanoparticle formulation in B16F10 melanoma. The
developed nanoparticles exhibited a sustained release action
in MTT assay suggesting great advantage over otherwise short
acting Cisplatin. These results are also exempliﬁed in clono-
genic and wound scratch assays. Developed nanoparticles
could cause a change in the morphology of cancerous cell lines
similar to the pure drug. In cell cycle analysis, these nanocar-
riers proved to be superior to Cisplatin by causing cell cycle
FITC DAPI Merged image
Plain dyes
Albumin 
Nanoparcles
Figure 9 Qualitative cell uptake by confocal microscopy.
Key                                 Name                                Parameter                               Gate
B16F10 cells only                         FLH-1                                     G1
Nanoparticles 2.5 µg/15 min                 FLH-1                                     G1
Nanoparticles 2.5 µg/30 min                 FLH-1                                     G1   
Nanoparticles 5 µg/15 min                    FLH-1                                     G1
Nanoparticles 5 µg/30 min            FLH-1                                     G1   
Figure 10 Quantitative cellular uptake by ﬂow cytometry.
350 S.S. Shrikhande et al.arrest in S phase in addition to G2/M phase along with supe-
rior cellular uptake as seen from qualitative and quantitative
studies. Hence, this study paves a way for therapy of mela-
noma by formulating Cisplatin in novel drug delivery systems
like nanoparticles.
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